Curtissnedker2072

Strategy for Chronic Coronary Syndrome - PCI or optimal medical therapy Abstract. In the new guidelines of the European Society of Cardiology (ESC), the previous term "stable coronary artery disease (CAD)" was replaced by a new term "chronic coronary syndrome (CCS)" in order to highlight the chronic but also progressive pathological character of CAD. Both optimal medical therapy and myocardial revascularization play a central role in the treatment of patients with CCS. However, due to the heterogeneity of CCS, it is a challenge to determine in clinical practice which patients may benefit from percutaneous coronary intervention (PCI). In addition, the importance of PCI is still controversial, especially in patients with CCS. Hence, this review discusses diagnostic and therapeutic approaches in patients with CCS considering the current ESC-guidelines and the ISCHEMIA Trial (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) in order to outline the optimal strategy for improving symptoms and prognosis.Recanalisation of chronic total coronary occlusions - what is the evidence and which patients will benefit? Abstract. Continuous improvement of recanalisation techniques and newer device technologies significantly improved the success of revascularisation in percutaneous coronary intervention (PCI) of chronic total occluded coronary arteries (CTO) in the past few years. The best documented clinical benefit of CTO-PCI is symptom control, based on a reduction of myocardial ischemia. In contrast, there is still an ongoing controversial debate regarding the prognostic benefit of successful CTO-PCI shown in several observational studies. Therefore, the indication for CTO-PCI is primarily based on patients' symptoms and the extent of myocardial ischemia. The risk / benefit ratio for the individual patient has to be estimated from technical complexity of the CTO lesion, the extent of the coronary artery disease and the ventricular function. Recanalisation strategy should be escalating, as most of the CTOs can be successfully recanalised with standard antegrade recanalisation techniques. With the implementation of retrograde CTO techniques, the likelihood for recanalisation success is very high (> 90 %) even in complex anatomies, combined with low complication rates in specialised centers. According to the operator's expertise a complete catheter-based revascularisation can be achieved nowadays even in patients with CTO and coronary multi-vessel disease.Bioresorbable vascular scaffolds - is therapy already at an end or is there a renaissance? Abstract. The principle of bioresorbable vascular scaffolds is a good approach to solving the residual problem of percutaneous coronary interventions, which despite the introduction and immense further development of metal stents have shown a continuous increase in undesirable events over the years. As an advantage, bioresorbable vascular scaffolds can on the one hand ensure the restoration of the physiological vascular properties; on the other hand - after resorption - in contrast to permanent metal implants, the cause of the development of in-stent re-stenoses or late stent thromboses, which still represent the greatest limitation of the metal stents, is resolved. The first real representative of the bioresorbable vascular scaffolds (Absorb) was able to deliver good results initially; but that could not be confirmed in the end, so that it was withdrawn from the market. However, important insights were gained from the error analyzes that influenced the further development of the currently approved scaffolds, so that scaffolds are now on the market that have a strut thickness comparable to metal stents and thereby produce good study results. BAI1 Even if the number of patients treated and the quality of the studies are not yet sufficient to change the current European guidelines, which are solely based on the Absorb-data; there is a promising data situation now compared to 2018 when the guidelines were written. The promising results of the studies in the treatment of infrapopliteal stenosis and the attendance of manufacturers to work on further product generations show that the therapy with BRS is far from over but is - after a bumpy start - at the beginning of a renaissance.Intracoronary imaging - an essential tool on the way to an individualized therapy of coronary artery disease? Abstract. Since decades, coronary angiography is the standard method to assess coronary anatomy and guide percutaneous coronary intervention. However, coronary angiography is limited to the lumen and a resolution of 200 - 300 micrometers. Thus, anything beyond is not detectable. Intracoronary imaging methods by means of intravascular ultrasound (IVUS) and particularly optical coherence tomography (OCT), provide incremental effects on coronary diagnostics and therapeutic decisions. Plaque burden and -composition (lipid, fibrous, calcific tissue, intramural hematoma), small intraluminal structures (thrombus), and implanted stents are uniquely detectable by intracoronary imaging. The use of these techniques inevitably leads to improved precision in coronary diagnostics and optimization of stent implantation.Treatment of Heavily Calcified Coronary Lesions Abstract. In Switzerland and other industrialized nations, coronary heart disease (CHD) is the most common cause of death in adulthood. CHD is a chronic disease in which stenoses of the epicardial coronary arteries usually cause a deficit in blood supply to the heart muscle tissue, which can lead to chest pain, myocardial infarction, heart failure or cardiac arrhythmia and ultimately to significant morbidity and mortality. Since the first percutaneous coronary intervention (PCI) on 16th September 1977 at the University Hospital of Zurich by Andreas Grüntzig, the field of interventional cardiology has seen remarkable progress in the treatment of coronary artery disease, especially with the development and evolution of coronary stents. Nonetheless, calcified coronary stenoses pose a challenge in everyday interventional practice because they prevent stent implantation or correct expansion or are associated with a higher rate of complications. Unfortunately, to date, there are no established interventions to prevent calcification of the coronary arteries.